Skip to content
naulon
Get started

Corrected on Aug 13, 2018.

Source: the publisher, via Crossref · checked Oct 19, 2026 · Read the notice

Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials

Ibrahim Jantan, Waqas Ahmad, Syed Nasir Abbas Bukhari

Frontiers in Plant Science · 2015 · Review

doi:10.3389/fpls.2015.00655

Abstract

The phagocyte-microbe interactions in the immune system is a defense mechanism but when excessively or inappropriately deployed can harm host tissues and participate in the development of different non-immune and immune chronic inflammatory diseases such as autoimmune problems, allergies, some rheumatoid disorders, cancers and others. Immunodrugs include organic synthetics, biological agents such as cytokines and antibodies acting on single targets or pathways have been used to treat immune-related diseases but with limited success. Most of immunostimulants and immunosuppressants in clinical use are the cytotoxic drugs which possess serious side effects. There is a growing interest to use herbal medicines as multi-component agents to modulate the complex immune system in the prevention of infections rather than treating the immune-related diseases. Many therapeutic effects of plant extracts have been suggested to be due to their wide array of immunomodulatory effects and influence on the immune system of the human body. Phytochemicals such as flavonoids, polysaccharides, lactones, alkaloids, diterpenoids and glycosides, present in several plants, have been reported to be responsible for the plants immunomodulating properties. Thus the search for natural products of plant origin as new leads for development of potent and safe immunosuppressant and immunostimulant agents is gaining much major research interest. The present review will give an overview of widely investigated plant-derived compounds (curcumin, resveratrol, epigallocatechol-3-gallate, quercetin, colchicine, capsaicin, andrographolide, and genistein) which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Immunity is the body’s natural defense system against various infectious diseases. The factors which trigger immunity include previous infection, immunization, and various external stimuli. Besides, immunity is capable of discriminating among body’s own proteins/cells and foreign entities. As soon as the foreign particle is identified, the collective and coordinated response of specific cells and mediators against strange substances constitutes the immune response. Based on the function, immune system has been categorized in two broad categories, i.e., innate immune system (non-specific immune system) and adaptive immune system (specific or acquired immune system; ). The microbiological, chemical and physical barriers are also sometimes included in innate immunity, however, the main mediators of immune system which deliver instant defense include cytokines, acute phase proteins, macrophages, monocytes, complement, and neutrophils. Various distinct moieties expressed by pathogens, known as pathogen-associated molecular patterns (PAMPs), are recognized by host to detect presence of a pathogen. The germline-encoded and evolutionarily conserved host sensors known as pattern recognition receptors (PRRs) recognize the PAMPs. Once the PRRs recognize the PAMPs, an array of immune responses are quickly triggered via induction of different type I interferons, chemokines, and cytokines. An important role in host’s defense is played by PRRs families such as DNA receptors (cytosolic sensors for DNA), NOD-like receptors, RIG-I-like receptors and toll-like receptors. All phases of non-specific immunity include antigen-presenting cells and macrophages which play pivotal roles in antibody-dependent cell-mediated cytotoxicity, secretion of cytokines, nitric oxide (NO) production and antigen presentation, processing and phagocytosis. Dendritic cells are responsible for the activation of naïve and memory B and naïve T cells. During various phases of dendritic cells’ differentiation, the effectors of innate immunity including natural killer (NK) cells are regulated, which govern specific and natural immune responses by producing tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and granulocyte–macrophage colony-stimulating factor (GM-CSF; ). Complement system is the tertiary relevant component of innate immunity. The complement system is the humoral immunity’s main effector among all the physiological systems of host defense. C3a and C3b (complement system’s components) are activated by C9, and amplify and mediate immune response.

Adaptive immunity is acquired by generating pathogen (antigen)-specific B and T lymphocytes through a gene rearrangement process. The exposure of body to antigen with aim to produce adaptive immune reaction that develops in weeks/months but may last through whole life is called active immunity. The active immunity may either be acquired or natural. The immune system of higher animals is equipped with adaptive immunity. The antigen specific reactions (via B and T lymphoctyes) are involved in adaptive immunity. The strong phagocytic action of myeloid cells and cytotoxic T lymphocytes is enhanced by Th1 lymphocytes which produce TNF-α, IFN-γ, and IL-2. The IL-4, IL-5, and IL-10 are produced by Th2 lymphocytes (which are the mediators of humoral immunity), categorized by B lymphocytes-mediated production of antibodies. The toxins or microorganisms are neutralized after binding with the antibodies. Moreover, antibodies have the ability to opsonize different pathogens, immobilize bacteria, and trigger microorganisms’ destruction by phagocytes via activation of complement proteins. The cell types involved in innate and adaptive immune responses are summarized in Figure 1.

Immunomodulators

In healthy organism, the immune system maintains homeostasis within the body. The function and efficiency of the immune system are influenced by various exogenous and endogenous factors resulting in either immunosuppression or immunostimulation. Several agents possessing an activity to normalize or modulate pathophysiological processes are called immunomodulators. The biomolecules of synthetic or biological origin capable of modulating, suppressing and stimulating any components of adaptive or innate immunity are known as immunomodulators, immunorestoratives, immunoaugmentors, or biological response modifiers. Immunomodulators are generally categorized into immunoadjuvants, immunostimulants, and immunosuppressants in clinical practice. Immunoadjuvants are specific immune stimulators which enhance the efficacy of vaccine. Agents that activate or induce the mediators or components of immune system are called as immunostimulants. The resistance against autoimmunity, cancer, allergy, and infection is enhanced by immunostimulants. On the other hand, immunosuppressants are the molecules that inhibit the immune system, can be used to control the pathological immune reaction subsequent to organ transplantation. Additionally, these agents can also be used in the treatment of infection-associated immunopathology, hypersensitivity reactions, and autoimmune diseases. A number of monoclonal antibodies and chemically synthesized compounds are also being used as immunomodulators. However, there are major limitations to the general use of these agents which are summarized in Table 1. Therefore, immunomodulatory entities with additional safety and effectiveness are still in need. Due to the occurrence of chemical drugs-related adverse effects, natural immunomodulators are the potential agents to replace them in therapeutic regimens.

Presently, majority of research and development still focuses on biochemicals, biologics, or single compounds as lead compounds that aim at particular targets linked with a disease. It is difficult to attain single compound chemicals with high selectivity and potency, and low toxicity for targeted molecular/cellular targets and diseases. Hence, the design and development of drug candidates from numerous conventional or complementary and alternative medicines is gaining interest. The prevention and treatment of disease using plant-based medicines has been reported in human history. In all cultures and through all ages different parts of a huge number of plants were used as drugs against all kinds of ailments. Vinblastine, vincristine and their semi-synthetic derivatives isolated from the Madagascar periwinkle (Catharanthus roseus), capsaicin from chili peppers (Capsicum species), paclitaxel from Pacific yew (Taxus brevifolia) and galantamine from the Caucasian snowdrop (Galanthus caucasicus) are examples of medicines based on plant compounds. The plant-based compounds that served as lead structures and/or were chemically altered are dicoumarol (warfarin), artemisinin (artemether), camptothecin (topotecan and irinotecan), morphine (scores of derivatives), and salicylic acid (acetylsalicylic acid; ).

Recently the clinical potential of six plant-derived antiinflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted in. The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.

The immunomodulatory characteristics of plant-based therapeutics have gathered attention of researchers. Innovative technologies and the excessive research on immunomodulatory natural products, plants, their extracts, and their active moieties with immunomodulatory potential, may provide us with valuable entities to develop as novel immunomodulatory agents to supplement the present chemotherapies. This review focuses on the plant-based immunomodulatory compounds undergoing clinical trials. Additionally, the potential use as immunomodulatory agents, modes of action and plant origin of numerous important plant-based lead compounds has also been comprehensively discussed (Figure 2). Beside these compounds, other phytochemicals including essential oils, steroids, terpenoids, phenolics, pigments, flavonoids, and alkaloids, etc. have exhibited worth mentioning immunomodulatory effect. Plant-derived compounds showing promising potential as immunomodulatory agents are listed in Table 2.

Curcumin

Curcumin is a natural diarylheptanoid compound found in the rhizome of Curcuma longa and related species. The medicinal benefits of curcumin have been known since centuries. A variety of biological and pharmacological properties of curcumin has been reported including anti-cancer, anti-oxidant, anti-angiogenic, anti-proliferative, pro-apoptotic, etc. Curcumin is one of the most extensively studied compound for its immunomodulatory properties. Curcumin lessened inflammatory responses by inhibiting NO production, cyclooxygenase-2 (COX-2), nuclear factor-kappa B (NK-kB), inducible nitric oxide synthase (iNOS), and lipoxygenase in NK cells and IFN-γ, or TNF-α activated macrophages. In phorbol 12-myristate 13- acetate (PMA) and H2O2-stimulated human myelomonoblastic cell line, curcumin inhibited NF-κB activation via prevention of degradation and phosphorylation of I kappa B alpha (IκB-α; ). Protein kinase C, which regulates the proliferation and survival of cell, is activated by PMA. Additionally, LPS and TNF-α also activate protein kinase C, which then activates NF-κB. Therefore, curcumin might weaken NF-kB activation by the inhibition of protein kinase C. The anti-inflammatory activity of curcumin was partially mediated by inhibiting activator protein (AP)-1 and transcription factor NF-κB. NF-κB and AP-1 act collectively and may enhance tumor development. The treatment of glioma cells with 25 μM curcumin reduced the binding of NF-κB and AP-1. The AP-1 activation was also suppressed by curcumin in TNF-activated bovine aortic endothelial cells. The activated immune cells release pro-inflammatory cytokines that play key role in inflammation. The expression of pro-inflammatory cytokines TNF-α, IL-1, IL-6, and IL-12 was inhibited by curcumin via LPS- or PMA-stimulated monocytes, macrophages, dendritic cells, and splenic lymphocytes. The attachment of T cells to endothelial and antigen presenting cells is dependent on cell adhesion molecules. The attachment of monocytes to endothelial cells was blocked by pre-treatment with curcumin. Moreover, the expression of intracellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and endothelial leukocyte adhesion molecule (ELAM)-1 was also decreased in TNF-α-stimulated human umbilical vein endothelial cells (HUVECs) via inhibition of NF-κB.

reviewed pre-clinical and clinical trials of curcumin that were carried out at different places. Presently, 116 studies regarding the diverse actions of curcumin could be found on http://www.clinicaltrials.gov/. Among these 99 studies were based on the anti-inflammatory properties of curcumin. The most noticeable diseases for which trials had been conducted were cancer (e.g., lung, prostate, breast, pancreatic, and colorectal), rheumatoid arthritis and inflammatory bowel diseases (IBD; ulcerative colitis and Crohn’s disease), which reflect the pleiotropic actions of curcumin. This information shows that curcumin is still under extensive clinical investigation. Future clinical trials will predominantly deal with still ongoing various types of cancer and the action of curcumin on cognitive damage. Additionally, the inflammatory conditions will still be studied. Curcumin often acts as an adjunct treatment or dietary supplement to the standard therapy in these trials. The review on effects of curcumin in ulcerative colitis stated that curcumin, when given as adjunct therapy may be effective and safe therapy for the maintenance of remission in quiescent ulcerative colitis. Nonetheless, more operationally thorough randomized controlled trials are required. This conclusion from the authors reflects the overall situation. However, suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods. The future of curcumin as an approved option for the prevention or treatment of the above mentioned indications relies on the findings of high-quality and big cohort studies in the future. Still, from the available literature, a conclusion can be drawn that curcumin exhibits good safety profile; it is nontoxic and well tolerated.

Resveratrol

Resveratrol, chemically (5-[(E)-2-(4-hydroxyphenyl) ethenyl] benzene-1,3-diol), is a derivative of stilbene and phytoalexin. It is found in various dietary products and plants including grapevines, red wine and peanuts. Similar to curcumin, resveratrol was found to exert a variety of pharmacological activities such as antimicrobial, chemopreventive, anticancer/proapoptotic, anti-inflammatory, and antioxidant properties. The inflammatory molecules are strongly inhibited by resveratrol. The immunomodulatory activities of resveratrol include the inhibition of NF-κB in PMA, LPS or TNF-α-mediated macrophages, epithelial (HeLa), Jurkat, myeloid (U-937) and dendritic cells. NF-κB activation was inhibited by resveratrol via inhibition of IκB kinase. The expression of COX-2 and iNOS in cytokine (IFN, IL-1, or TNF-α) stimulated human primary airway epithelial cells was also inhibited by resveratrol whereas it also blocked the transcription of COX-2 in human mammary epithelial cells stimulated by PMA. The secretion of NO and TNF-α in LPS-activated N9 microglial and cortical microglia cells was also substantially suppressed by resveratrol, moreover the production of IL-12, IL-6, IL-1, TNF-α, and IFN-γ and by splenic macrophages and lymphocytes was also inhibited. Resveratrol also showed strong inhibition of in vivo C5 anaphylatoxin (C5a)-mediated inflammation. The release of inflammatory cytokines (MIP-1, IL-6, IL-1, and TNF-α) in C5a-activated mouse and human neutrophils was inhibited by the pre-incubation with resveratrol (10–40 M). In addition, ERK-phosphorylation, release of glucuronide and C5a induced oxidative burst (superoxide anion production) were also inhibited by resveratrol. Furthermore, resveratrol inhibited production of inflammatory cytokines and C5a-stimulated neutrophil recruitment/migration in C5a-stimulated acute peritonitis mouse model. The expression of cell adhesion molecules was also found to be inhibited by resveratrol. The IL-6-stimulated ICAM-1 expression in endothelial cells was also decreased by resveratrol, in addition to the inhibition of Porphyromonas gingivalis LPS-induced endothelial dysfunction in human microvascular endothelial cells. Besides, ICAM-1 and VCAM-1 expression on human microvascular endothelial cells was blocked by inhibition of NF-κB activation.

Based on the above-mentioned findings, a lot of emphasis was put into the explanation of the underlying mechanisms of action. Still, this enormous knowledge has yet not been translated into anapproved clinical medicine. More than 40 clinical trials on resveratrol have been listed in PubMed for a variety of diseases like coronary artery disease, obesity, diabetes, and so forth. The main focus of these studies was to either analyze inflammation-related parameters in blood cells (e.g., transcription factors or activated kinases) and in plasma (e.g., IL-6, IL-1β, TNF-α) or to report on functional parameters like the status of the endothelium. Several trials persuasively showed that these parameters are usefully influenced by resveratrol. Though, whether this improved inflammatory status of the patients indeed leads to a clinically relevant improvement of the severity of the diseases or, most significantly, in a decreased incidence of disease-specific life-threatening events has not been studied. Currently 99 studies are listed on http://www.clinicaltrials.gov/, 49 studies have been completed while 28 clinical trials on resveratrol are currently recruiting or planned. Among them 27 studies are linked with the anti-inflammatory properties of resveratrol. The main field of interest is metabolic syndrome/type 2 diabetes, followed by mild cognitive impairment, non-alcoholic fatty liver disease, and polycystic ovary syndrome. Research would benefit by carrying out interventional studies with definite primary outcomes reflecting the stage or/and occurrence of the diseases on a long-term basis.

Epigallocatechin-3-gallate

One of the most active and abundant polyphenol of green tea Camellia sinensis (Theaceae) is epigallocatechin-3-gallate (EGCG), chemically [(2R,3R)-5,7-dihydroxy-2-(3,4, 5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl]3,4,5-trihydroxybenzoate]. It has been widely reported for its in vitro and in vivo chemopreventive, anti-angiogenic, anti-invasive, anti-proliferative, anti-inflammatory, and anti-oxidant effects. Studies have showed that EGCG blocked the activation of NF-κB by inhibiting the degradation of IκBα and also inhibited the MAPK pathways. The down-regulation of iNOS transcription and NO production in macrophages is dependent on the inhibition of NF-κB. In comparison, it was shown that EGCG improved the production of NO to inhibit endothelial exocytosis and leukocyte adherence to endothelial cells. Moreover, it was reported that EGCG blocked NF-κB activation in human endothelial cells and thus inhibited the expression of MCP-1. By reducing mRNA expression of bax and caspase3 and by decreasing caspase3 activity, EGCG also decreased apoptosis. Additionally, it inhibited expression of COX-2, proteasome dependent degradation, the MAPK pathway and growth factor-dependent signaling (e.g., of IGF-I, VEGF, and EGF; ). Likewise, EGCG inhibited DNA methyltransferase 1, topoisomerase II and telomerase, thus affecting the functions of chromatin.

Surprisingly, though, notwithstanding encouraging pre-clinical results and the detailed mechanistic insights, clinical studies related to inflammation are lacking. A small scale study investigated the action of green tea and its extract on biomarkers of inflammation (e.g., ICAM-1, VCAM-1, IL-1β, IL-6, CRP, and adiponectin) in obese patients with metabolic syndrome. After 8 weeks treatment, green tea did not change the biomarker levels. Another clinical trial reported a useful impact of topical EGCG treatment on acne vulgaris, which may be in part due to anti-inflammatory effects. A green tea extract was approved as a prescription drug in 2006 for the topical treatment of anal and genital warts (Condylomata acuminate). This key development fueled additional research to expand the indications of EGCG. Sixty-eight clinical trials are listed on http://www.clinicaltrials.gov/ for upcoming years. Fifteen studies are in recruiting stage while 33 studies have been completed. EGCG will be tested for its effects on albuminuria in diabetic nephropathy along with its action in patients with multiple-system atrophy, Huntington’s disease, fragile X syndrome, Down syndrome, Alzheimer’s disease (early stage), muscular dystrophy of the Duchenne type, and cardiac amyloid light-chain amyloidosis. Furthermore, the trials will study the potential of EGCG on preventing colon polyps in patients at high risk for recurrent colon adenoma and on reactivation of the Epstein–Barr virus in remission patients. More studies will investigate whether topical EGCG exerts an anticarcinogenic potential in patients with superficial basal cell carcinoma, whether gargling with EGCG inhibits influenza infections in teenagers and whether EGCG affects the resistance of insulin. Evidently, the trials will not study classic inflammatory disorder, though some of the mentioned diseases are linked with inflammatory processes (e.g., insulin resistance or Alzheimer’s disease). Nonetheless, it is probable that EGCG will experience an expansion of its indication in future.

Quercetin

The flavonol, quercetin, chemically 2-(3,4-dihydroxyphenyl)- 3,5,7-trihydroxychromen-4-one, belongs to the family of polyphenols representing very extensively spread secondary plant metabolites. Quercetin is found in a variety of food like tea, capers, red onions, broccoli, berries, grapevines, and apples. Quercetin has been found to exert anti-mutagenic, anti-oxidative, anti-inflammatory, anticancer/chemopreventive, neuroprotective, antihypertensive, and blood glucose-lowering activities. Quercetin activated various kinases which phosphorylated eukaryotic initiation factor 2, thus inhibiting cell translation. The mechanisms behind these actions are wide and have been characterized extensively. Quercetin scavenged nitrogen and reactive oxygen species (ROS), targets noticeable pro-inflammatory signaling pathways including MAPK, NF-κB and STAT1, and inhibits replication of many types of viruses and infectivity of target cells. The activity of COX-2 and iNOS was inhibited by quercitin by the suppression of AP-1, NF-κB and STAT-1 signaling in cytokine- or LPS-induced HUVECs and macrophages. The expression of pro-inflammatory cytokines in calcium ionophore- and PMA-induced mast cells was attenuated by quercitin. Moreover, the TNF-α-stimulated NF-κB recruitment to pro-inflammatory gene promoters was also suppressed by quercitin in murine intestinal epithelial cells. The TNF-α- or PMA-induced expression of ICAM-1 in human endothelial cells was decreased by quercitin. The LPS-stimulated NF-κB and nitrite oxide production was also inhibited by quercitin in mice.

A number of studies on inflammatory parameters in humans have been performed in the past few years: one clinical trial estimated the effect of quercetin on biomarkers of inflammation depending on the apo-lipoprotein E genotype of healthy men. Though the risk factors of cardiovascular disease were improved, quercetin exerted a slight pro-inflammatory effect. After repeated sprint exercise, quercetin did not affect the levels of the pro-inflammatory cytokine IL-6. Quercetin decreased the markers of inflammation (IL-8 and TNF-α) in sarcoidosis patients. Quercetin did not change phagocytosis activity, granulocyte oxidative burst or blood leukocyte subsets, TNF-α or IL-6 plasma levels in healthy females. It is worth mentioning that no trial reports on the improvement of clinical parameters of inflammatory diseases (incidence and severity). Ten trials are registered on http://www.clinicaltrials.gov/ that will use pure quercetin. Regarding inflammatory disorders, quercetin will be analyzed in two-phase 1–2 trials for its dose-response relationship and safety in chronic obstructive pulmonary disease. For diabetes, quercetin will be tested in a phase 2 trial for its effect on blood vessel function and blood glucose in type 2 diabetes. Quercetin will also be administered in obese patients (with or without type 2 diabetes) to investigate its action on glucose absorption. In study related to cancer, it will be studied whether quercetin can prevent prostate cancer and whether it controls levels of prostate-specific antigen. Additionally, quercetin will be administered in children with Fanconi anemia (pharmacokinetics and safety). Therefore, quercetin will go through interesting studies that may lead to insightful development of knowledge regarding its clinical efficacy. Though, inflammatory diseases are not the main areas of current research.

Colchicine

The tropolone derivative, colchicine, chemically (N-[(7S)-1,2, 3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo(a)heptalen-7] -ylacetamide), is the main alkaloid of Colchicum autumnale (family: Colchicaceae), generally called meadow saffron or autumn crocus. The extracts of this plant have been used against gout attacks for centuries. The US FDA has approved colchicine for the prevention and treatment of familial mediterranean fever and acute gout flares. To obtain this approval, the applying company provided new clinical data and was thus given an exclusive marketing agreement, 7 years for familial Mediterranean fever and 3 years for the indication gout (orphan drug status). The mechanisms of action of colchicine are extensively studied: the molecular target was recognized, the binding spot was accurately characterized, and the biological consequences of damaging microtubule dynamics were examined; complete reviews summarizing these results are available. In 1960s, colchicine played a key role for the initial characterization of tubulin subunits and microtubules.

In spite of this vast knowledge, researchers have recently conducted numerous trials to expand its fields of application. Several trials in the field of inflammation-associated pathologies with positive outcome: colchicine was tested as an adjunct treatment against acute pericarditis. In an open-label, single-center randomized trial, colchicine addition to glucocorticoids or aspirin traditional treatment reduced the reappearance to half, after early occurrence of acute pericarditis. In a placebo controlled, double-blind, randomized, multicenter trial, colchicine, when added to traditional anti-inflammatory therapy, substantially decreased the rate of recurrent or incessant pericarditis, to prevent atrial fibrillation after radiofrequency ablation and for the prevention of post-pericardiotomy syndrome. These well-performed and large studies will definitely affect pharmacotherapy guidelines. And the field is still active: 19 clinical trials that are in the recruiting phase, are listed on http://www.clinicaltrials.gov/. They aim to study the action of colchicine primarily in the areas of nephrology and cardiology, for instance, in myocardial infarction, for the prevention of post-pericardiotomy syndrome, or in diabetic nephropathy-all related to inflammatory processes. Colchicine will be investigated to determine its effects on metabolism in adults who are overweight but have not yet developed diabetes. As the number of diseases with an inflammatory component is large, one might wonder that colchicine will further stay an interesting, not yet fully used drug.

Capsaicin

Capsaicin, chemically (E)-N-[(4-hydroxy-3-methoxyphenyl) methyl]-8-methylnon-6-enamide, is a hydrophobic alkaloid found in chili peppers (Capsicum species; Solanaceae) and accounts for the characteristic spiciness/pungency of the fruits of the genus. It has been used in traditional medicine as a counter-irritant and topical rubefacient to relieve pain of joints and muscles. Recently, an 8% capsaicin cutaneous patch has been approved by the EU for use in non-diabetic adults against neuropathic pain and in US against neuropathic pain linked with post-herpetic neuralgia. The research on capsaicin resulted in the discovery of transient receptor potential channel vanilloid subfamily member 1 (TRPV1), which is the direct target of capsaicin. TRPV1 is a positively charged indiscriminate channel mainly located in nociceptive neurons with high preference for Ca2+. It is activated by physical and chemical stimuli, like certain inflammatory mediators, capsaicin, low pH and heat. Extended activation of TRPV1 by capsaicin was found to cause desensitization and, therefore, decreased pain sensation. Apart from pain, numerous studies in arthritic rats also discovered that capsaicin could inhibit paw inflammation and ethanol-induced inflammation of gastric mucosa in rats. Furthermore, capsaicin was found to inhibit NF-κB pathway, iNOS expression and COX-2 activity in the macrophages in a TRPV1-independent manner. Regarding inflammation, capsaicin was studied in a latest review by the Cochrane Collaboration: topical capsaicin was discovered to be ineffective against osteoarthritis. In comparison, one meta-analysis found adequate evidence to report that capsaicin was effective in the management of osteoarthritis, though the authors reported the lacking of randomized clinical trials. As far as future therapeutic enhancements are concerned, 24 clinical trials are currently recruiting or are planned, as listed on http://www.clinicaltrials.gov/. Majority of these studies use capsaicin as a model substance to induce pain or as a diagnostic tool. Studies that examine the therapeutic potential of capsaicin study its potential as pre-emptive analgesic in patients going through amputation of a limb and its effect on neuropathic pain from critical ischemia (mainly in feet and hands) and on chronic pain from artificial arteriovenous fistulae in end-stage renal failure patients. Besides, capsaicin will be tested against the decreased swallow response in stroke patients with or opharyngeal dysphagia and against persistent pain after inguinal herniotomy. A study on the mechanism of action of capsaicin against idiopathic rhinitis will be carried out. No study will investigate the immunomodulatory effects of capsaicin. It can be concluded that, in comparison with neuropathic pain, the field of inflammation and capsaicin is not very cutting-edge and will stay on that level in the near future owing to lack of clinical trials.

Andrographolide

Andrographolide is a diterpenoid lactone found in Andrographis paniculata. Chemically, it is (3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5, 8-dimethyl-2-methylene-1-napthalenyl] ethylidene] dihydro- 4-hydroxy-2(3H)-furanone). Diverse biological activities have been exhibited by andrographolide. Numerous immunomodulatory activities of andrographolide have been observed in vitro including reduction of IL-12, TNF-α, PGE2, NO, COX-2 and iNOS in microglia and macrophages. The LPS-stimulated iNOS and COX-2 expression in RAW264.7 macrophages was inhibited by andrographolide. It also inhibited Akt and Erk ½ signaling, consequently inhibiting the chemotactic migration of macrophages on the site of inflammation. In neutrophils, the production of ROS was inhibited by andrographolide. Andrographolide regulated the production of factors such as NK cells, IFN-γ, IL-2, and TNF-α. The administration of andrographolide resulted in improved expression of CD markers and production of TNF-α, therefore increasing the cytotoxic potential of lymphocytes. Andrographolide inhibited IL-2, IFNγ and IL-6 expression, decreasing the cellular and humoral adaptive immune reaction in T cells. Andrographolide decreased the antigen-presenting potential of dendritic cells to T cells. In an ovalbumin-induced asthma rat model, the andrographolide administration decreased the serum immunoglobulin, IL-13, IL-4, IL-5, and Th2 cytokine. Andrographolide decreased migration and invasion, endothelial cell proliferation and adhesion molecule ICAM-1, signifying its role in angiogenesis. The functions of NF-κB were inhibited by a number of immunomodulatory responses and andrographolide inhibited NF-κB binding to DNA and hence decreasing pro-inflammatory proteins expression like iNOS and COX-2. Andrographolide down regulated COX-2 and iNOS gene expression by inhibiting NF-κB and signal transducer and activator of transcription-3 (STAT3) expression via suppressing the expression of suppressor of cytokine signaling 1 and 3. conducted a study to determine the effect of andrographolide on insulinoma tumor growth. Andrographolide was found to inhibit the progression of insulinoma tumor by targeting the TLR4/NF-κB signaling pathway.

In spite of this vast knowledge, researchers have recently conducted numerous trials to expand its fields of application. But most of the trials have been conducted by using the crude extract. A double blind study was conducted on 101 patients with moderately active Crohn’s disease to assess the efficacy and safety of aqueous ethanol extract of A. paniculata. At week 8 of treatment, a significant decrease in the mean C-reactive protein level was observed in extract treated group as compared with the placebo group. A phase II study in patients with mildly to moderately active ulcerative colitis demonstrated that the efficacy of the aqueous ethanol extract of A. paniculata was similar to that of slow release mesalazine. In contrast to the patients with mildly to moderately active ulcerative colitis receiving placebo, those treated with A. paniculata extract were more probable to attain clinical response. In a double blind against placebo controlled clinical trial, the standardized patented A. paniculata extract’s (Paractin®) effect was evaluated in chronic rheumatoid arthritis patients. A significant reduction in total grade of tender joints, number of tender joints, total grade of swollen joint, number of swollen joints was observed. Serological parameters and rheumatoid factor (C4 and IgA) of disease were found to be reduced. Currently, five different studies related to the various actions of andrographolide could be found on http://www.clinicaltrials.gov/. Two trials are registered on http://www.clinicaltrials.gov/ that will use pure andrographolide. A double blind, interventional, randomized, and placebo controlled phase II trial will determine the safety, acceptability, and effectiveness of andrographolide in active rheumatoid arthritis-affected patients and effects on the immunological functions that effect chronic inflammation will also be determined. A study will be conducted to determine the efficacy of andrographolide in retarding the progression of brain atrophy in patients with progressive forms of multiple sclerosis. Besides, the efficacy and safety of andrographolide will also be evaluated for the treatment of colorectal cancer.

Genistein

Genistein, chemically 4,5,7-trihydroxyisoflavone, is a naturally occurring phytoestrogen, present in soy and soy-derived items. Genistein is a renowned tyrosine kinase inhibitor. In vitro, genistein inhibited IL-1b/IFNγ-induced COX-2 and iNOS expression and in addition to producing PGE2 and NO in human islets that may prevent pathogenesis of diabetes and improve insulin resistance. Like other topoisomerase inhibitors, genistein induced apoptosis. Genistein strongly inhibited angiogenesis, exerted inhibiting effect on proliferating cells. Genistein regulates vascular function and protects from atherosclerosis. The administration of genistein in human brain microvascular endothelial cells and HUVECs significantly inhibited the expression of TNF-α-induced cell adhesion molecule CD106 and CD62E, and monocyte adhesion. Genistein also reduced the interaction between endothelial cells and monocyte via activation of PPARs that reduced monocyte adhesion in culture cells and animals. The LPS-stimulated secretion of MCP-1 from macrophages was inhibited by genistein that resulted in decreased migration of monocyte in vitro. Genistein inhibited LPS-induced expression of nitro tyrosine protein and iNOS in vascular tissue that inhibits vascular alterations and hypotension in vivo. Genistein exerted potential effect on chronic colitis, neurodegenerative diseases, rheumatoid arthritis, metabolic disorders, and diabetes by modulating inflammatory response. For example, genistein inhibited production of pro-inflammatory molecules called as markers of cartilage catabolism (HC gp-39, IL-1b, and NO) in LPS-induced human chondrocytes. Genistein modulated Th1-predominant immune response by increasing IL-4 production and suppressing the secretion of IFN-γ in a collagen-induced rheumatoid arthritis rat. NAFLD is an obesity-linked fatty liver illness sourced by pro-inflammatory cytokines and TNF-α and results in increase fatty acid uptake and the dysfunction of hepatocytes. Genistein reduced the high fat diet-induced steatohepatitis by improving liver function and decreasing plasma TNF-α level in rat. Moreover, genistein reduced LPS-stimulated dopamine uptake loss in rat mesencephalic neuron glial cells by decreasing production of TNF-α and NO and microglia activation this might protect the pathogenesis of Parkinson’s disease caused by dopaminergic neuron injury. The increase of astrocytes at Ab deposition sites is the initial neuropathological fluctuation that starts inflammation in Alzheimer’s disease. The production of Ab-stimulated inflammatory mediators IL-1β, TNF-α, COX-2, and iNOS in astrocytes was decreased by genistein treatment, probably by PPARs’ activation. Likewise, oral administration of genistein decreased TNBS-stimulated chronic colitis by inhibition of COX-2 mRNA and protein expression together with the colonic myeloperoxidase (MPO) activity in rat that applies useful anti-inflammatory effects in the treatment of IBD.

Genistein has undergone clinical trials for a variety of diseases like type 2 diabetes mellitus, menopause, osteopenia, and various types of cancer. The most noticeable diseases for which trails had been conducted were cancer. Genistein is undergoing clinical trials for chemopreventive and chemotherapeutic purposes in various cancers. Currently 11 open clinical trials have been in recruiting or planned according to http://www.clinicaltrials.gov. The main field of interest is cancer (colon cancer; rectal cancer; colorectal cancer, prostate cancer, bladder cancer, adenocarcinoma, pancreatic adenocarcinoma) followed by osteoporosis, hypercholesterolemia, Alzheimer’s disease and menopause.

Conclusions and Future Prospects

Natural products and folklore medicines are the main contributors of the leads in the design and development of therapeutic agents. Several plant derived compounds have been identified over the years for their immunomodulatory characteristics. Numerous illnesses can be alternatively treated by immunomodulation using medicinal plants, instead of chemotherapy. The discovery and isolation of more specific immunomodulatory agents from plant origin possesses potential to counteract the side effects and high cost of synthetic compounds. This review highlights the significance of medicinal plants as producers of immunomodulatory molecules of very varied chemistries with possible uses in animal and human health. The challenges encountered by the application of plant-derived immunomodulators need to be addressed. Though, the path from traditional medicines to western pharmaceutical practices is not always easy. The inconsistency of responses of phytomedical practices can be clarified in terms of the typically strong reliance of plant secondary metabolite profiles on environmental signals that can disturb reproducibility of results with extracts. This can be decreased if the principles of standardization of extracts and enriched fractions are thoroughly applied.

In most of studies conducted to determine the effect on immune system, no adequate microbial contamination control protocols were applied. Researchers report that the microbial endotoxin can change the parameters of immune system. Therefore, appropriate precautions must be taken to counter the microbial contamination. An additional task is the classification of plant-derived immunomodulatory agents in a specific class or among classes as per inherent risk. This classification of novel plant derived immunomodulatory agents by level of risk can be endeavored from collective knowledge of meta-analyses of clinical trials, national registries and physicians. Another significant constraint with natural products is inadequate quantities, needed for development and clinical use. So, the development of novel isolation techniques to improve the amount for pharmaceutical applications needs more attention of researchers. A major clinical restraint of these substances is the low bioavailability. Nanotechnology and other delivery strategies are being applied to enhance their efficacy when administered to humans. Lastly, there is a deficiency of standard checking and quality control procedures to assure the efficacy and quality of the plant derived medicinal products for prospective pharmaceutical applications. A few plant derived compounds, including polysaccharides, are extremely diversified in terms of molecular weight and structure; therefore, it is challenging to produce the similar quality in every batch. Accumulative requirement for these plant-derived products would motivate improvement to overwhelming these obstacles for reaching market.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 193

  1. 1.

    Abbey E. L. Rankin J. W. (2011 ). Effect of quercetin supplementation on repeated-sprint performance, xanthine oxidase activity, and inflammation. Int. J. Sport Nutr. Exerc. Metab. 21 91–96.

    Not in our library10.1123/ijsnem.21.2.91

  2. 2.

    Ammon H. P. (2006 ). Boswellic acids in chronic inflammatory diseases. Planta Med. 72 1100–1116.

    Not in our library10.1055/s-2006-947227

  3. 3.

    Anand P. Kunnumakkara A. B. Newman R. A. Aggarwal B. B. (2007 ). Bioavailability of curcumin: problems and promises. Mol. Pharm. 4 807–818.

    Not in our library10.1021/mp700113r

  4. 4.

    Andújar I. Recio M. C. Bacelli T. Giner R. M. Rios J. L. (2010 ). Shikonin reduces oedema induced by phorbol ester by interfering with IκBα degradation thus inhibiting translocation of NF-κB to the nucleus. Br. J. Pharmacol. 160 376–388.

    Not in our library10.1111/j.1476-5381.2010.00696.x

  5. 5.

    Auffenberg C. Rosenthal L. J. Dresner N. (2013 ). Levamisole: a common cocaine adulterant with life-threatening side effects. Psychosomatics 54 590–593.

    Not in our library10.1016/j.psym.2013.02.012

  6. 6.

    Bae Y. Lee S. Kim S.-H. (2011 ). Chrysin suppresses mast cell-mediated allergic inflammation: involvement of calcium, caspase-1 and nuclear factor-κB. Toxicol. Appl. Pharmacol. 254 56–64.

    Not in our library10.1016/j.taap.2011.04.008

  7. 7.

    Bakker G. C. Van Erk M. J. Pellis L. Wopereis S. Rubingh C. M. Cnubben N. H. (2010 ). An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am. J. Clin. Nutr. 91 1044–1059.

    Not in our library10.3945/ajcn.2009.28822

  8. 8.

    Bandele O. J. Osheroff N. (2008 ). (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem. Res. Toxicol. 21 936–943.

    Not in our library10.1021/tx700434v

  9. 9.

    Bartelds G. M. Krieckaert C. L. Nurmohamed M. T. Van Schouwenburg P. A. Lems W. F. Twisk J. W. (2011 ). Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305 1460–1468.

    Not in our library10.1001/jama.2011.406

  10. 10.

    Basu A. Du M. Sanchez K. Leyva M. J. Betts N. M. Blevins S. (2011 ). Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 27 206–213.

    Not in our library10.1016/j.nut.2010.01.015

  11. 11.

    Baudouin V. Crusiaux A. Haddad E. Schandene L. Goldman M. Loirat C. (2003 ). Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 76 459–463.

    Not in our library10.1097/01.tp.0000073809.65502.8f

  12. 12.

    Bauer J. Koeberle A. Dehm F. Pollastro F. Appendino G. Northoff H. (2011 ). Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. Biochem. Pharmacol. 81 259–268.

    Not in our library10.1016/j.bcp.2010.09.025

  13. 13.

    Baxter D. (2007 ). Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. 57 552–556.

    Not in our library10.1093/occmed/kqm110

  14. 14.

    Berger J. R. Houff S. A. Major E. O. (2009 ). Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 1 583–589.

    Not in our library10.4161/mabs.1.6.9884

  15. 15.

    Bermejo A. Zarzuelo A. Duarte J. (2003 ). In vivo vascular effects of genistein on a rat model of septic shock induced by lipopolysaccharide. J. Cardiovasc. Pharmacol. 42 329–338.

    Not in our library10.1097/00005344-200309000-00003

  16. 16.

    Bhattacharyya B. Panda D. Gupta S. Banerjee M. (2008 ). Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med. Res. Rev. 28 155–183.

    Not in our library10.1002/med.20097

  17. 17.

    Bhaumik S. Jyothi M. D. Khar A. (2000 ). Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 483 78–82.

    Not in our library10.1016/s0014-5793(00)02089-5

  18. 18.

    Bi X. L. Yang J. Y. Dong Y. X. Wang J. M. Cui Y. H. Ikeshima T. (2005 ). Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. Int. Immunopharmacol. 5 185–193.

    Not in our library10.1016/j.intimp.2004.08.008

  19. 19.

    Boots A. W. Drent M. De Boer V. C. Bast A. Haenen G. R. (2011 ). Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin. Nutr. 30 506–512.

    Not in our library10.1016/j.clnu.2011.01.010

  20. 20.

    Boots A. W. Haenen G. R. Bast A. (2008 ). Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol. 585 325–337.

    Not in our library10.1016/j.ejphar.2008.03.008

  21. 21.

    Borisy G. G. Taylor E. W. (1967 ). The mechanism of action of colchicine. colchicine binding to sea urchin eggs and the mitotic apparatus. J. Cell Biol. 34 535–548.

    Not in our library10.1083/jcb.34.2.535

  22. 22.

    Brinker A. M. Ma J. Lipsky P. E. Raskin I. (2007 ). Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68 732–766.

    Not in our library10.1016/j.phytochem.2006.11.029

  23. 23.

    Burgos R. A. Hancke J. L. Bertoglio J. C. Aguirre V. Arriagada S. Calvo M. (2009 ). Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clin. Rheumatol. 28 931–946.

    Not in our library10.1007/s10067-009-1180-5

  24. 24.

    Cameron M. Chrubasik S. (2013 ). Topical herbal therapies for treating osteoarthritis. Cochrane Database Syst. Rev. 5 CD010538.

    Not in our library10.1002/14651858.cd010538

  25. 25.

    Campoli-Richards D. Sorkin E. Heel R. (1986 ). Inosine Pranobex. Drugs 32 383–424.

    Not in our library10.2165/00003495-198632050-00001

  26. 26.

    Caterina M. J. Schumacher M. A. Tominaga M. Rosen T. A. Levine J. D. Julius D. (1997 ). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 816–824.

    Not in our library10.1038/39807

  27. 27.

    Chacko B. K. Chandler R. T. D’alessandro T. L. Mundhekar A. Khoo N. K. Botting N. (2007 ). Anti-inflammatory effects of isoflavones are dependent on flow and human endothelial cell PPAR gamma. J. Nutr. 137 351–356.

    Not in our library10.1093/jn/137.2.351

  28. 28.

    Chandrashekar N. Selvamani A. Subramanian R. Pandi A. Thiruvengadam D. (2012 ). Baicalein inhibits pulmonary carcinogenesis-associated inflammation and interferes with COX-2, MMP-2 and MMP-9 expressions in-vivo. Toxicol. Appl. Pharmacol. 261 10–21.

    Not in our library10.1016/j.taap.2012.02.004

  29. 29.

    Chen C. Y. Peng W. H. Tsai K. D. Hsu S. L. (2007 ). Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 81 1602–1614.

    Not in our library10.1016/j.lfs.2007.09.028

  30. 30.

    Chen D. Bi A. Dong X. Jiang Y. Rui B. Liu J. (2014 ). Luteolin exhibits anti-inflammatory effects by blocking the activity of heat shock protein 90 in macrophages. Biochem. Biophys. Res. Commun. 443 326–332.

    Not in our library10.1016/j.bbrc.2013.11.122

  31. 31.

    Chen D. P. Wong C. K. Leung P. C. Fung K. P. Lau C. B. Lau C. P. (2011 ). Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-alpha-activated human fibroblast-like synoviocytes in rheumatoid arthritis. J. Ethnopharmacol. 137 457–468.

    Not in our library10.1016/j.jep.2011.05.048

  32. 32.

    Chen Y.-C. Yang L. L. Lee T. J. F. (2000 ). Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-κB activation. Biochem. Pharmacol. 59 1445–1457.

    Not in our library10.1016/s0006-2952(00)00255-0

  33. 33.

    Chiou W. F. Chen C. F. Lin J. J. (2000 ). Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br. J. Pharmacol. 129 1553–1560.

    Not in our library10.1038/sj.bjp.0703191

  34. 34.

    Choi S. J. Tai B. Cuong N. Kim Y. H. Jang H. D. (2012 ). Antioxidative and anti-inflammatory effect of quercetin and its glycosides isolated from mampat (Cratoxylum formosum). Food Sci. Biotechnol. 21 587–595.

    Not in our library10.1007/s10068-012-0075-4

  35. 35.

    Chung J. Choi R. Seo E.-K. Nam J.-W. Dong M.-S. Shin E. (2012 ). Anti-inflammatory effects of (Z)-ligustilide through suppression of mitogen-activated protein kinases and nuclear factor-κB activation pathways. Arch. Pharm. Res. 35 723–732.

    Not in our library10.1007/s12272-012-0417-z

  36. 36.

    Chung J. Y. Park J. O. Phyu H. Dong Z. Yang C. S. (2001 ). Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3’-digallate. FASEB J. 15 2022–2024.

    Not in our library10.1096/fj.01-0031fje

  37. 37.

    Corbett J. A. Kwon G. Marino M. H. Rodi C. P. Sullivan P. M. Turk J. (1996 ). Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Am. J. Physiol. 270 C1581–C1587.

    Not in our library10.1152/ajpcell.1996.270.6.c1581

  38. 38.

    Daikonya A. Katsuki S. Kitanaka S. (2004 ). Antiallergic agents from natural sources 9. Inhibition of nitric oxide production by novel chalcone derivatives from Mallotus philippinensis (Euphorbiaceae). Chem. Pharm. Bull. 52 1326–1329.

    Not in our library10.1248/cpb.52.1326

  39. 39.

    Deftereos S. Giannopoulos G. Kossyvakis C. Efremidis M. Panagopoulou V. Kaoukis A. (2012 ). Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol. 60 1790–1796.

    Not in our library10.1016/j.jacc.2012.07.031

  40. 40.

    De Silva V. El-Metwally A. Ernst E. Lewith G. Macfarlane G. J. (2011 ). Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology 50 911–920.

    Not in our library10.1093/rheumatology/keq379

  41. 41.

    Dhandapani K. M. Mahesh V. B. Brann D. W. (2007 ). Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFκB transcription factors. J. Neurochem. 102 522–538.

    Not in our library10.1111/j.1471-4159.2007.04633.x

  42. 42.

    Donnelly L. E. Newton R. Kennedy G. E. Fenwick P. S. Leung R. H. Ito K. (2004 ). Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol. Lung. Cell. Mol. Physiol. 287 4

    Not in our library10.1152/ajplung.00110.2004

  43. 43.

    Fan G. W. Zhang Y. Jiang X. Zhu Y. Wang B. Su L. (2013 ). Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and Nf-κB-dependent pathways. Inflammation 36 1584–1591.

    Not in our library10.1007/s10753-013-9703-2

  44. 44.

    Fotsis T. Pepper M. Adlercreutz H. Hase T. Montesano R. Schweigerer L. (1995 ). Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr. 125 790S–797S.

    Not in our library10.1093/jn/125.suppl_3.790s

  45. 45.
    Plant-Derived Anti-Inflammatory Compounds: Hopes and Disappointments regarding the Translation of Preclinical Knowledge into Clinical Progress · 2014
    No notice
  46. 46.

    Gao X. Kuo J. Jiang H. Deeb D. Liu Y. Divine G. (2004 ). Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem. Pharmacol. 68 51–61.

    Not in our library10.1016/j.bcp.2004.03.015

  47. 47.

    Gao X. Xu Y. X. Janakiraman N. Chapman R. A. Gautam S. C. (2001 ). Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol. 62 1299–1308.

    Not in our library10.1016/s0006-2952(01)00775-4

  48. 48.

    Gao Y. Jiang W. Dong C. Li C. Fu X. Min L. (2012 ). Anti-inflammatory effects of sophocarpine in LPS-induced RAW 264.7 cells via NF-κB and MAPKs signaling pathways. Toxicol. In Vitro 26 1–6.

    Not in our library10.1016/j.tiv.2011.09.019

  49. 49.

    Gilman’s G. (2008 ). Manual of Pharmacology and Therapeutics. San Diego LaJolla, CA: Professor of Pharmacology & Medicine University of California.

    Not in our library

  50. 50.

    Golan D. E. (2008 ). Principles of Pharmacology. The Pathophysiologic Basic of Drug Therapy, 2nd Edn Pennsylvania, PA: Lippincott Williams & Wilkins, 795–809.

    Not in our library

  51. 51.

    Guo Q. Zhao L. You Q. Yang Y. Gu H. Song G. (2007 ). Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res. 74 16–24.

    Not in our library10.1016/j.antiviral.2007.01.002

  52. 52.

    Haanpaa M. Treede R. D. (2012 ). Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur. Neurol. 68 264–275.

    Not in our library10.1159/000339944

  53. 53.
    Anti-Inflammatory Effects of Flavonoids: Genistein, Kaempferol, Quercetin, and Daidzein Inhibit STAT-1 and NF- κ B Activations, Whereas Flavone, Isorhamnetin, Naringenin, and Pelargonidin Inhibit only NF- κ B Activation along with Their Inhibitory Effect on iNOS Expression and NO Production in Activated Macrophages · 2007
    No notice
  54. 54.

    Hansel T. T. Kropshofer H. Singer T. Mitchell J. A. George A. J. (2010 ). The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9 325–338.

    Not in our library10.1038/nrd3003

  55. 55.

    Hara Y. Fujino M. Adachi K. Li X. K. (2006 ). The reduction of hypoxia-induced and reoxygenation-induced apoptosis in rat islets by epigallocatechin gallate. Transplant. Proc. 38 2722–2725.

    Not in our library10.1016/j.transproceed.2006.08.010

  56. 56.

    Hartog A. Smit H. F. Van Der Kraan P. M. Hoijer M. A. Garssen J. (2009 ). In vitro and in vivo modulation of cartilage degradation by a standardized Centella asiatica fraction. Exp. Biol. Med. 234 617–623.

    Not in our library10.3181/0810-rm-298

  57. 57.

    Heinz S. A. Henson D. A. Nieman D. C. Austin M. D. Jin F. (2010 ). A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects. Br. J. Nutr. 104 849–857.

    Not in our library10.1017/s000711451000156x

  58. 58.

    Hidalgo M. A. Romero A. Figueroa J. Cortes P. Concha I. I. Hancke J. L. (2005 ). Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br. J. Pharmacol. 144 680–686.

    Not in our library10.1038/sj.bjp.0706105

  59. 59.

    Holden N. S. Squires P. E. Kaur M. Bland R. Jones C. E. Newton R. (2008 ). Phorbol ester-stimulated NF-κB-dependent transcription: roles for isoforms of novel protein kinase C. Cell. Signal. 20 1338–1348.

    Not in our library10.1016/j.cellsig.2008.03.001

  60. 60.

    Holmes-McNary M. Baldwin A. S. Jr. (2000 ). Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res. 60 3477–3483.

    Not in our library

  61. 61.

    Hong M. H. Kim M. H. Chang H. J. Kim N. H. Shin B. A. Ahn B. W. (2007 ). (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-κB signaling. Life Sci. 80 1957–1965.

    Not in our library10.1016/j.lfs.2007.02.024

  62. 62.

    Hooshmand S. Soung Do Y. Lucas E. A. Madihally S. V. Levenson C. W. Arjmandi B. H. (2007 ). Genistein reduces the production of proinflammatory molecules in human chondrocytes. J. Nutr. Biochem. 18 609–614.

    Not in our library10.1016/j.jnutbio.2006.11.006

  63. 63.

    Hougee S. Sanders A. Faber J. Graus Y. M. F. Van Den Berg W. B. Garssen J. (2005 ). Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem. Pharmacol. 69 241–248.

    Not in our library10.1016/j.bcp.2004.10.002

  64. 64.

    Hu J.-Z. Huang J. H. Xiao Z. M. Li J. H. Li X. M. Lu H. B. (2013 ). Tetramethylpyrazine accelerates the function recovery of traumatic spinal cord in rat model by attenuating inflammation. J. Neurol. Sci. 324 94–99.

    Not in our library10.1016/j.jns.2012.10.009

  65. 65.

    Imazio M. Bobbio M. Cecchi E. Demarie D. Demichelis B. Pomari F. (2005a ). Colchicine in addition to conventional therapy for acute pericarditis: results of the colchicine for acute PEricarditis (COPE) trial. Circulation 112 2012–2016.

    Not in our library10.1161/circulationaha.105.542738

  66. 66.

    Imazio M. Bobbio M. Cecchi E. Demarie D. Pomari F. Moratti M. (2005b ). Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (Colchicine for REcurrent pericarditis) trial. Arch. Intern. Med. 165 1987–1991.

    Not in our library10.1001/archinte.165.17.1987

  67. 67.

    Imazio M. Brucato A. Cemin R. Ferrua S. Belli R. Maestroni S. (2011 ). Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann. Intern. Med. 155 409–414.

    Not in our library10.7326/0003-4819-155-7-201110040-00359

  68. 68.

    Imazio M. Brucato A. Cemin R. Ferrua S. Maggiolini S. Beqaraj F. (2013 ). A randomized trial of colchicine for acute pericarditis. N. Engl. J. Med. 369 1522–1528.

    Not in our library10.1056/nejmoa1208536

  69. 69.

    Imazio M. Trinchero R. Brucato A. Rovere M. E. Gandino A. Cemin R. (2010 ). Colchicine for the prevention of the post-pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur. Heart J. 31 2749–2754.

    Not in our library10.1093/eurheartj/ehq319

  70. 70.

    Iruretagoyena M. I. Tobar J. A. Gonzalez P. A. Sepulveda S. E. Figueroa C. A. Burgos R. A. (2005 ). Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J. Pharmacol. Exp. Ther. 312 366–372.

    Not in our library10.1124/jpet.104.072512

  71. 71.

    Issuree P. D. Pushparaj P. N. Pervaiz S. Melendez A. J. (2009 ). Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J. 23 2412–2424.

    Not in our library10.1096/fj.09-130542

  72. 72.

    Ito T. Warnken S. P. May W. S. (1999 ). Protein synthesis inhibition by flavonoids: roles of eukaryotic initiation factor 2alpha kinases. Biochem. Biophys. Res. Commun. 265 589–594.

    Not in our library10.1006/bbrc.1999.1727

  73. 73.

    Jain S. (2008 ). Handbook of Pharmacology. London: Pars Publication.

    Not in our library

  74. 74.

    Joe B. Rao U. J. Lokesh B. R. (1997 ). Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol. Cell. Biochem. 169 125–134.

    Not in our library10.1023/a:1006877928703

  75. 75.

    Jurenka J. S. (2009 ). Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev. 14 141–153.

    Not in our library

  76. 76.

    Kang H.-K. Ecklund D. Liu M. Datta S. K. (2009 ). Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res. Ther. 11 R59.

    Not in our library10.1186/ar2682

  77. 77.

    Kang J. Zhang Y. Cao X. Fan J. Li G. Wang Q. (2012 ). Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge. Int. Immunopharmacol. 12 249–256.

    Not in our library10.1016/j.intimp.2011.11.018

  78. 78.

    Kang S. R. Park K. I. Park H. S. Lee D. H. Kim J. A. Nagappan A. (2011 ). Anti-inflammatory effect of flavonoids isolated from Korea Citrus aurantium L. on lipopolysaccharide-induced mouse macrophage RAW 264.7 cells by blocking of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signalling pathways. Food Chem. 129 1721–1728.

    Not in our library10.1016/j.foodchem.2011.06.039

  79. 79.

    Kannaiyan R. Shanmugam M. K. Sethi G. (2011 ). Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303 9–20.

    Not in our library10.1016/j.canlet.2010.10.025

  80. 80.

    Katzung G. B. Trevor J. A. (2009 ). Basic and Clinical Pharmacology. New York, NY: Lange Medical Books/McGraw Hill, 2004.

    Not in our library

  81. 81.

    Keane J. Gershon S. Wise R. P. Mirabile-Levens E. Kasznica J. Schwieterman W. D. (2001 ). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345 1098–1104.

    Not in our library10.1056/nejmoa011110

  82. 82.

    Khajuria A. Gupta A. Garai S. Wakhloo B. P. (2007 ). Immunomodulatory effects of two sapogenins 1 and 2 isolated from Luffa cylindrica in Balb/C mice. Bioorg. Med. Chem. Lett. 17 1608–1612.

    Not in our library10.1016/j.bmcl.2006.12.091

  83. 83.

    Kim C. S. Kawada T. Kim B. S. Han I. S. Choe S. Y. Kurata T. (2003 ). Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cell. Signal. 15 299–306.

    Not in our library10.1016/s0898-6568(02)00086-4

  84. 84.

    Kim G. Y. Kim K. H. Lee S. H. Yoon M. S. Lee H. J. Moon D. O. (2005 ). Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-κB as potential targets. J. Immunol. 174 8116–8124.

    Not in our library10.4049/jimmunol.174.12.8116

  85. 85.

    Kim S. Y. Moon K. A. Jo H. Y. Jeong S. Seon S. H. Jung E. (2012 ). Anti-inflammatory effects of apocynin, an inhibitor of NADPH oxidase, in airway inflammation. Immunol. Cell Biol. 90 441–448.

    Not in our library10.1038/icb.2011.60

  86. 86.

    Kim S. Shin H. J. Kim S. Y. Kim J. H. Lee Y. S. Kim D. H. (2004 ). Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol. Cell. Endocrinol. 220 51–58.

    Not in our library10.1016/j.mce.2004.03.011

  87. 87.

    Kleemann R. Verschuren L. Morrison M. Zadelaar S. Van Erk M. J. Wielinga P. Y. (2011 ). Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218 44–52.

    Not in our library10.1016/j.atherosclerosis.2011.04.023

  88. 88.

    Kobuchi H. Roy S. Sen C. K. Nguyen H. G. Packer L. (1999 ). Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway. Am. J. Physiol. 277 C403–C411.

    Not in our library10.1152/ajpcell.1999.277.3.c403

  89. 89.

    Koeberle A. Pollastro F. Northoff H. Werz O. (2009 ). Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br. J. Pharmacol. 156 952–961.

    Not in our library10.1111/j.1476-5381.2009.00070.x

  90. 90.

    Kong L. Luo C. Li X. Zhou Y. He H. (2013 ). The anti-inflammatory effect of kaempferol on early atherosclerosis in high cholesterol fed rabbits. Lipids Health Dis. 12 112–115.

    Not in our library10.1186/1476-511x-12-115

  91. 91.

    Kowalski J. Samojedny A. Paul M. Pietsz G. Wilczok T. (2005 ). Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-1beta and tumor necrosis factor-alpha genes in J774.2 macrophages. Pharmacol. Rep. 57 390–394.

    Not in our library

  92. 92.

    Kumar A. Dhawan S. Hardegen N. J. Aggarwal B. B. (1998 ). Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappa B activation. Biochem. Pharmacol. 55 775–783.

    Not in our library10.1016/s0006-2952(97)00557-1

  93. 93.

    Kumar R. A. Sridevi K. Kumar N. V. Nanduri S. Rajagopal S. (2004 ). Anticancer and immunostimulatory compounds from Andrographis paniculata. J. Ethnopharmacol. 92 291–295.

    Not in our library10.1016/j.jep.2004.03.004

  94. 94.

    Kumar S. Ahuja V. Sankar M. J. Kumar A. Moss A. C. (2012 ). Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 10 CD008424

    Not in our library10.1002/14651858.cd008424.pub2

  95. 95.

    Lee H. N. Cho H. J. Lim D. Y. Kang Y.-H. Lee K. W. Park J. H. Y. (2013a ). Mechanisms by which licochalcone e exhibits potent anti-inflammatory properties: studies with phorbol ester-treated mouse skin and lipopolysaccharide-stimulated murine macrophages. Int. J. Mol. Sci. 14 10926–10943.

    Not in our library10.3390/ijms140610926

  96. 96.

    Lee I. T. Lin C. C. Lee C. Y. Hsieh P. W. Yang C. M. (2013b ). Protective effects of (-)-epigallocatechin-3-gallate against TNF-α-induced lung inflammation via ROS-dependent ICAM-1 inhibition. J. Nutr. Biochem. 24 124–136.

    Not in our library10.1016/j.jnutbio.2012.03.009

  97. 97.

    Lee K. C. Chang H. H. Chung Y. H. Lee T. Y. (2011 ). Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-κB pathway. J. Ethnopharmacol. 135 678–684.

    Not in our library10.1016/j.jep.2011.03.068

  98. 98.

    Lee W. Ku S.-K. Bae J.-S. (2015 ). Anti-inflammatory effects of Baicalin, Baicalein, and Wogonin in vitro and in vivo. Inflammation 38 110–125.

    Not in our library10.1007/s10753-014-0013-0

  99. 99.

    Lee W. J. Shim J. Y. Zhu B. T. (2005 ). Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 68 1018–1030.

    Not in our library10.1124/mol.104.008367

  100. 100.

    Lee Y. W. Lee W. H. (2008 ). Protective effects of genistein on proinflammatory pathways in human brain microvascular endothelial cells. J. Nutr. Biochem. 19 819–825.

    Not in our library10.1016/j.jnutbio.2007.10.006

  101. 101.

    Li H. Gong X. Zhang L. Zhang Z. Luo F. Zhou Q. (2009 ). Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice. Phytomedicine 16 538–546.

    Not in our library10.1016/j.phymed.2008.11.002

  102. 102.

    Li P. Yin Y. L. Li D. Kim S. W. Wu G. (2007 ). Amino acids and immune function. Br. J. Nutr. 98 237–252.

    Not in our library10.1017/s000711450769936x

  103. 103.

    Lin W. C. Lin J. Y. (2011 ). Berberine down-regulates the Th1/Th2 cytokine gene expression ratio in mouse primary splenocytes in the absence or presence of lipopolysaccharide in a preventive manner. Int. Immunopharmacol. 11 1984–1990.

    Not in our library10.1016/j.intimp.2011.08.008

  104. 104.

    Liu H.-T. Du Y.-G. He J.-L. Chen W.-J. Li W.-M. Yang Z. (2010 ). Tetramethylpyrazine inhibits production of nitric oxide and inducible nitric oxide synthase in lipopolysaccharide-induced N9 microglial cells through blockade of MAPK and PI3K/Akt signaling pathways, and suppression of intracellular reactive oxygen species. J. Ethnopharmacol. 129 335–343.

    Not in our library10.1016/j.jep.2010.03.037

  105. 105.

    Liu L. Li Y. (2014 ). The unexpected side effects and safety of therapeutic monoclonal antibodies. Drugs Today 50 33–50.

    Not in our library10.1358/dot.2014.50.1.2076506

  106. 106.

    Liu X. Mei Z. Qian J. Zeng Y. Wang M. (2013 ). Puerarin partly counteracts the inflammatory response after cerebral ischemia/reperfusion via activating the cholinergic anti-inflammatory pathway. Neural Regen. Res. 8 3203

    Not in our library10.3969/j.issn.1673-5374.2013.34.004

  107. 107.

    Liu X. H. Pan L. L. Yang H. B. Gong Q. H. Zhu Y. Z. (2012 ). Leonurine attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: involvement of reactive oxygen species and NF-κB pathways. Eur. J. Pharmacol 680 108–114.

    Not in our library10.1016/j.ejphar.2012.01.012

  108. 108.

    Lucas C. D. Dorward D. A. Sharma S. Rennie J. Felton J. M. Alessandri A. L. (2015 ). Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation. Am. J. Respir. Crit. Care Med. 191 626–636.

    Not in our library10.1164/rccm.201408-1565oc

  109. 109.

    Maiti K. Gantait A. Mukherjee K. Saha B. Mukherjee P. K. (2006 ). Therapeutic potentials of andrographolide from Andrographis paniculata: a review. J. Nat. Remed. 6 1–13.

    Not in our library

  110. 110.

    Manna S. K. Mukhopadhyay A. Aggarwal B. B. (2000 ). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164 6509–6519.

    Not in our library10.4049/jimmunol.164.12.6509

  111. 111.

    Mccabe M. J. Jr. Orrenius S. (1993 ). Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase-II. Biochem. Biophys. Res. Commun. 194 944–950.

    Not in our library10.1006/bbrc.1993.1912

  112. 112.

    Middleton E. Jr. Kandaswami C. Theoharides T. C. (2000 ). The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52 673–751.

    Not in our library

  113. 113.

    Moradali M. F. Mostafavi H. Ghods S. Hedjaroude G. A. (2007 ). Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int. Immunopharmacol. 7 701–724.

    Not in our library10.1016/j.intimp.2007.01.008

  114. 114.

    Muraoka K. Shimizu K. Sun X. Tani T. Izumi R. Miwa K. (2002 ). Flavonoids exert diverse inhibitory effects on the activation of NF-κB. Transplant. Proc. 34 1335–1340.

    Not in our library10.1016/s0041-1345(02)02795-1

  115. 115.

    Mythili M. Nair S. Gunasekaran S. (2004 ). Effect of cyclophosphamide pretreatment on hematological indices of Indian Bonnet monkeys. Indian J. Pharmacol. 36 175.

    Not in our library

  116. 116.

    Nagarajan S. Burris R. L. Stewart B. W. Wilkerson J. E. Badger T. M. (2008 ). Dietary soy protein isolate ameliorates atherosclerotic lesions in apolipoprotein E-deficient mice potentially by inhibiting monocyte chemoattractant protein-1 expression. J. Nutr. 138 332–337.

    Not in our library10.1093/jn/138.2.332

  117. 117.

    Nicholas C. Batra S. Vargo M. A. Voss O. H. Gavrilin M. A. Wewers M. D. (2007 ). Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-κB through the suppression of p65 phosphorylation. J. Immunol. 179 7121–7127.

    Not in our library10.4049/jimmunol.179.10.7121

  118. 118.

    Niu X. F. Zhou P. Li W. F. Xu H. B. (2011 ). Effects of chelerythrine, a specific inhibitor of cyclooxygenase-2, on acute inflammation in mice. Fitoterapia 82 620–625.

    Not in our library10.1016/j.fitote.2011.01.020

  119. 119.

    Nuki G. (2008 ). Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 10 218–227.

    Not in our library10.1007/s11926-008-0036-3

  120. 120.

    Oberlies N. H. Kroll D. J. (2004 ). Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod. 67 129–135.

    Not in our library10.1021/np030498t

  121. 121.

    Oh S. R. Kinjo J. Shii Y. Ikeda T. Nohara T. Ahn K. S. (2000 ). Effects of triterpenoids from Pueraria lobata on immunohemolysis: beta-D-glucuronic acid plays an active role in anticomplementary activity in vitro. Planta Med. 66 506–510.

    Not in our library10.1055/s-2000-8614

  122. 122.

    Oh Y. C. Kang O. H. Kim S. B. Mun S. H. Park C. B. Kim Y. G. (2012 ). Anti-inflammatory effect of sinomenine by inhibition of pro-inflammatory mediators in PMA plus A23187-stimulated HMC-1 Cells. Eur. Rev. Med. Pharmacol. Sci. 16 1184–1191.

    Not in our library

  123. 123.

    O’Neill J. Brock C. Olesen A. E. Andresen T. Nilsson M. Dickenson A. H. (2012 ). Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol. Rev. 64 939–971.

    Not in our library10.1124/pr.112.006163

  124. 124.

    Park H. H. Lee S. Son H. Y. Park S. B. Kim M. S. Choi E. J. (2008 ). Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch. Pharm. Res. 31 1303–1311.

    Not in our library10.1007/s12272-001-2110-5

  125. 125.

    Park H. J. Jeong S. K. Kim S. R. Bae S. K. Kim W. S. Jin S. D. (2009 ). Resveratrol inhibits Porphyromonas gingivalis lipopolysaccharide-induced endothelial adhesion molecule expression by suppressing NF-κB activation. Arch. Pharm. Res. 32 583–591.

    Not in our library10.1007/s12272-009-1415-7

  126. 126.

    Park H. J. Shin D. H. Chung W. J. Leem K. Yoon S. H. Hong M. S. (2006 ). Epigallocatechin gallate reduces hypoxia-induced apoptosis in human hepatoma cells. Life Sci. 78 2826–2832.

    Not in our library10.1016/j.lfs.2005.11.001

  127. 127.

    Park J. S. Choi M. A. Kim B. S. Han I. S. Kurata T. Yu R. (2000 ). Capsaicin protects against ethanol-induced oxidative injury in the gastric mucosa of rats. Life Sci. 67 3087–3093.

    Not in our library10.1016/s0024-3205(00)00890-0

  128. 128.

    Parkin J. Cohen B. (2001 ). An overview of the immune system. Lancet 357 1777–1789.

    Not in our library10.1016/s0140-6736(00)04904-7

  129. 129.

    Parnham M. J. Nijkamp F. P. (2005 ). Principles of Immunopharmacology. Basel: Birkhauser Verlag.

    Not in our library

  130. 130.

    Pfeuffer M. Auinger A. Bley U. Kraus-Stojanowic I. Laue C. Winkler P. (2013 ). Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr. Metab. Cardiovasc. Dis. 23 403–409.

    Not in our library10.1016/j.numecd.2011.08.010

  131. 131.

    Puri A. Saxena R. Saxena R. P. Saxena K. C. Srivastava V. Tandon J. S. (1994 ). Immunostimulant activity of Nyctanthes arbor-tristis L. J. Ethnopharmacol. 42 31–37.

    Not in our library10.1016/0378-8741(94)90020-5

  132. 132.

    Qin L. H. Kong L. Shi G. J. Wang Z. T. Ge B. X. (2006 ). Andrographolide inhibits the production of TNF-alpha and interleukin-12 in lipopolysaccharide-stimulated macrophages: role of mitogen-activated protein kinases. Biol. Pharm. Bull. 29 220–224.

    Not in our library10.1248/bpb.29.220

  133. 133.

    Rajagopal S. Kumar R. A. Deevi D. S. Satyanarayana C. Rajagopalan R. (2003 ). Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J. Exp. Ther. Oncol. 3 147–158.

    Not in our library10.1046/j.1359-4117.2003.01090.x

  134. 134.

    Ramgolam V. Ang S. G. Lai Y. H. Loh C. S. Yap H. K. (2000 ). Traditional Chinese medicines as immunosuppressive agents. Ann. Acad. Med. Singapore 29 11–16.

    Not in our library

  135. 135.

    Rang H. P. Dale M. M. (2007 ). Rang and Dale Pharmacology. Edinburgh: Churchill Livingestone.

    Not in our library

  136. 136.

    Richard A. H. Pamela C. C. (2009 ). Lippincott’s Illustrated Reviews: Pharmacology, 4th Edn New Delhi: Wolters Kluwer.

    Not in our library

  137. 137.

    Ruiz P. A. Braune A. Holzlwimmer G. Quintanilla-Fend L. Haller D. (2007 ). Quercetin inhibits TNF-induced NF-κB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J. Nutr. 137 1208–1215.

    Not in our library10.1093/jn/137.5.1208

  138. 138.

    Sadava D. Whitlock E. Kane S. E. (2007 ). The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem. Biophys. Res. Commun. 360 233–237.

    Not in our library10.1016/j.bbrc.2007.06.030

  139. 139.

    Sandborn W. Targan S. Byers V. Tang T. (2010 ). Randomized, double-blind, placebo controlled trial of Andrographis paniculata extract (HMPL-004) in patients with moderately active Crohn’s disease. Am. J. Gastroenterol. 105(Suppl. 1), s429–s430.

    Not in our library

  140. 140.

    Sandborn W. J. Targan S. R. Byers V. S. Rutty D. A. Mu H. Zhang X. (2013 ). Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am. J. Gastroenterol. 108 90–98.

    Not in our library10.1038/ajg.2012.340

  141. 141.

    Seibel J. Molzberger A. F. Hertrampf T. Laudenbach-Leschowski U. Diel P. (2009 ). Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur. J. Nutr. 48 213–220.

    Not in our library10.1007/s00394-009-0004-3

  142. 142.

    Sengupta P. R. (2009 ). Medical Pharmacology. New Delhi: CBS Publisher.

    Not in our library

  143. 143.

    Sgro C. (1995 ). Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105 23–29.

    Not in our library10.1016/0300-483x(95)03123-w

  144. 144.

    Shaik Y. B. Castellani M. L. Perrella A. Conti F. Salini V. Tete S. (2006 ). Role of quercetin (a natural herbal compound) in allergy and inflammation. J. Biol. Regul. Homeost. Agents 20 47–52.

    Not in our library

  145. 145.

    Shen Y. C. Chen C. F. Chiou W. F. (2002 ). Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br. J. Pharmacol. 135 399–406.

    Not in our library10.1038/sj.bjp.0704493

  146. 146.

    Shin E. K. Kwon H. S. Kim Y. H. Shin H. K. Kim J. K. (2009 ). Chrysin, a natural flavone, improves murine inflammatory bowel diseases. Biochem. Biophys. Res. Commun. 381 502–507.

    Not in our library10.1016/j.bbrc.2009.02.071

  147. 147.

    Si H. Liu D. (2007 ). Phytochemical genistein in the regulation of vascular function: new insights. Curr. Med. Chem 14 2581–2589.

    Not in our library10.2174/092986707782023325

  148. 148.

    Singh B. N. Shankar S. Srivastava R. K. (2011 ). Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 82 1807–1821.

    Not in our library10.1016/j.bcp.2011.07.093

  149. 149.

    Singh S. Aggarwal B. B. (1995 ). Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 270 24995–25000.

    Not in our library10.1074/jbc.270.42.24995

  150. 150.

    Singhal K. C. (2007 ). Essentials of Pharmacotherapeutics. New Delhi: CBS Publishers.

    Not in our library

  151. 151.

    Son D. J. Akiba S. Hong J. T. Yun Y. P. Hwang S. Y. Park Y. H. (2014 ). Piperine inhibits the activities of platelet cytosolic phospholipase A2 and thromboxane A2 synthase without affecting cyclooxygenase-1 activity: different mechanisms of action are involved in the inhibition of platelet aggregation and macrophage inflammatory response. Nutrients 6 3336–3352.

    Not in our library10.3390/nu6083336

  152. 152.

    Song J. Y. Han S. K. Son E. H. Pyo S. N. Yun Y. S. Yi S. Y. (2002 ). Induction of secretory and tumoricidal activities in peritoneal macrophages by ginsan. Int. Immunopharmacol. 2 857–865.

    Not in our library10.1016/s1567-5769(01)00211-9

  153. 153.

    Song X. Wang T. Zhang Z. Jiang H. Wang W. Cao Y. (2015 ). Leonurine exerts anti-inflammatory effect by regulating inflammatory signaling pathways and cytokines in lps-induced mouse mastitis. Inflammation 38 79–88.

    Not in our library10.1007/s10753-014-0009-9

  154. 154.

    Song Y. Qu R. Zhu S. Zhang R. Ma S. (2012 ). Rhynchophylline attenuates LPS-induced pro-inflammatory responses through down-regulation of MAPK/NF-κB signaling pathways in primary microglia. Phytother. Res. 26 1528–1533.

    Not in our library10.1002/ptr.4614

  155. 155.

    Spellberg B. Edwards J. E. Jr. (2001 ). Type 1/Type 2 immunity in infectious diseases. Clin. Infect. Dis 32 76–102.

    Not in our library10.1086/317537

  156. 156.

    Stanton R. A. Gernert K. M. Nettles J. H. Aneja R. (2011 ). Drugs that target dynamic microtubules: a new molecular perspective. Med. Res. Rev. 31 443–481.

    Not in our library10.1002/med.20242

  157. 157.
    Apocynin: Molecular Aptitudes · 2008
    No notice
  158. 158.

    Strayer D. R. Carter W. A. (2012 ). Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J. Interferon Cytokine Res. 32 95–102.

    Not in our library10.1089/jir.2011.0069

  159. 159.

    Surh Y. J. Chun K. S. Cha H. H. Han S. S. Keum Y. S. Park K. K. (2001 ). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat. Res. 481 243–268.

    Not in our library10.1016/s0027-5107(01)00183-x

  160. 160.

    Tang T. Targan S. R. Li Z. S. Xu C. Byers V. S. Sandborn W. J. (2011 ). Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment. Pharmacol. Ther. 33 194–202.

    Not in our library10.1111/j.1365-2036.2010.04515.x

  161. 161.

    Tome-Carneiro J. Larrosa M. Yanez-Gascon M. J. Davalos A. Gil-Zamorano J. Gonzalvez M. (2013 ). One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 72 69–82.

    Not in our library10.1016/j.phrs.2013.03.011

  162. 162.

    Tortora G. J. Derrickson B. P. (2008 ). Principles of Anatomy and Physiology, 12th Edn Hoboken, NJ: John Wiley & Sons Inc.

    Not in our library

  163. 163.

    Tsai H. R. Yang L. M. Tsai W. J. Chiou W. F. (2004 ). Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. Eur. J. Pharmacol 498 45–52.

    Not in our library10.1016/j.ejphar.2004.07.077

  164. 164.

    Vaibhav K. Shrivastava P. Javed H. Khan A. Ahmed M. E. Tabassum R. (2012 ). Piperine suppresses cerebral ischemia–reperfusion-induced inflammation through the repression of COX-2, NOS-2, and NF-κB in middle cerebral artery occlusion rat model. Mol. Cell. Biochem. 367 73–84.

    Not in our library10.1007/s11010-012-1321-z

  165. 165.

    Vaillancourt F. Silva P. Shi Q. Fahmi H. Fernandes J. C. Benderdour M. (2011 ). Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. J. Cell. Biochem. 112 107–117.

    Not in our library10.1002/jcb.22884

  166. 166.

    Valles S. L. Dolz-Gaiton P. Gambini J. Borras C. Lloret A. Pallardo F. V. (2010 ). Estradiol or genistein prevent Alzheimer’s disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res. 2 138–144.

    Not in our library10.1016/j.brainres.2009.11.044

  167. 167.
    What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol · 2011
    No notice
  168. 168.

    Vesely M. D. Kershaw M. H. Schreiber R. D. Smyth M. J. (2011 ). Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29 235–271.

    Not in our library10.1146/annurev-immunol-031210-101324

  169. 169.

    Wang J. Zhang Q. Jin S. He D. Zhao S. Liu S. (2008 ). Genistein modulate immune responses in collagen-induced rheumatoid arthritis model. Maturitas 59 405–412.

    Not in our library10.1016/j.maturitas.2008.04.003

  170. 170.

    Wang T. Liu B. Zhang W. Wilson B. Hong J. S. (2004 ). Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J. Pharmacol. Exp. Ther. 308 975–983.

    Not in our library10.1124/jpet.103.059683

  171. 171.

    Wang X. Chen S. Ma G. Ye M. Lu G. (2005 ). Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 16 267–270.

    Not in our library10.1097/00001756-200502280-00013

  172. 172.

    Wang Z. Lee Y. Eun J. S. Bae E. J. (2014 ). Inhibition of adipocyte inflammation and macrophage chemotaxis by butein. Eur. J. Pharmacol. 738 40–48.

    Not in our library10.1016/j.ejphar.2014.05.031

  173. 173.

    Wu C. J. Wang Y. H. Lin C. J. Chen H. H. Chen Y. J. (2011 ). Tetrandrine down-regulates ERK/NF-κB signaling and inhibits activation of mesangial cells. Toxicol In Vitro 25 1834–1840.

    Not in our library10.1016/j.tiv.2011.09.024

  174. 174.

    Wung B. S. Hsu M. C. Wu C. C. Hsieh C. W. (2005 ). Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci. 78 389–397.

    Not in our library10.1016/j.lfs.2005.04.052

  175. 175.

    Xia Y. F. Ye B. Q. Li Y. D. Wang J. G. He X. J. Lin X. (2004 ). Andrographolide attenuates inflammation by inhibition of NF-κB activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 173 4207–4217.

    Not in our library10.4049/jimmunol.173.6.4207

  176. 176.

    Xiang M. X. Xu Z. Su H. W. Hu J. Yan Y. J. (2011 ). Emodin-8-O-beta-D-glucoside from Polygonum amplexicaule D. Don var. sinense Forb. promotes proliferation and differentiation of osteoblastic MC3T3-E1 cells. Molecules 16 728–737.

    Not in our library10.3390/molecules16010728

  177. 177.

    Xu Y.-K. Liao S.-G. Na Z. Hu H.-B. Li Y. Luo H.-R. (2012 ). Gelsemium alkaloids, immunosuppressive agents from Gelsemium elegans. Fitoterapia 83 1120–1124.

    Not in our library10.1016/j.fitote.2012.04.023

  178. 178.

    Xu Y. X. Pindolia K. R. Janakiraman N. Chapman R. A. Gautam S. C. (1997 ). Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol. Mol. Hematol. 11 49–62.

    Not in our library

  179. 179.

    Yalniz M. Bahcecioglu I. H. Kuzu N. Poyrazoglu O. K. Bulmus O. Celebi S. (2007 ). Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J. Gastroenterol. Hepatol. 22 2009–2014.

    Not in our library10.1111/j.1440-1746.2006.04681

  180. 180.

    Yamakuchi M. Bao C. Ferlito M. Lowenstein C. J. (2008 ). Epigallocatechin gallate inhibits endothelial exocytosis. Biol. Chem. 389 935–941.

    Not in our library10.1515/bc.2008.095

  181. 181.

    Yang C. S. Wang H. Li G. X. Yang Z. Guan F. Jin H. (2011a ). Cancer prevention by tea: evidence from laboratory studies. Pharmacol. Res. 64 113–122.

    Not in our library10.1016/j.phrs.2011.03.001

  182. 182.

    Yang H. Landis-Piwowar K. Chan T. H. Dou Q. P. (2011b ). Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Curr. Cancer Drug Targets 11 296–306.

    Not in our library10.2174/156800911794519743

  183. 183.

    Ye M. Wang Q. Zhang W. Li Z. Wang Y. Hu R. (2014 ). Oroxylin A exerts anti-inflammatory activity on lipopolysaccharide-induced mouse macrophage via Nrf2/ARE activation. Biochem. Cell Biol. 92 337–348.

    Not in our library10.1139/bcb-2014-0030

  184. 184.

    Yoo H. Ku S.-K. Baek Y.-D. Bae J.-S. (2014 ). Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo. Inflam. Res. 63 197–206.

    Not in our library10.1007/s00011-013-0689-x

  185. 185.

    Yoon J. Y. Kwon H. H. Min S. U. Thiboutot D. M. Suh D. H. (2013 ). Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J. Invest. Dermatol. 133 429–440.

    Not in our library10.1038/jid.2012.292

  186. 186.

    Youn J. Lee J. S. Na H. K. Kundu J. K. Surh Y. J. (2009 ). Resveratrol and piceatannol inhibit iNOS expression and NF-κB activation in dextran sulfate sodium-induced mouse colitis. Nutr. Cancer 61 847–854.

    Not in our library10.1080/01635580903285072

  187. 187.

    Yu H. N. Ma X. L. Yang J. G. Shi C. C. Shen S. R. He G. Q. (2007 ). Comparison of effects of epigallocatechin-3-gallate on hypoxia injury to human umbilical vein, RF/6A, and ECV304 cells induced by Na(2)S(2)O(4). Endothelium 14 227–231.

    Not in our library10.1080/10623320701547299

  188. 188.

    Yun K. J. Shin J. S. Choi J. H. Back N. I. Chung H. G. Lee K. T. (2009 ). Quaternary alkaloid, pseudocoptisine isolated from tubers of Corydalis turtschaninovi inhibits LPS-induced nitric oxide, PGE2, and pro-inflammatory cytokines production via the down-regulation of NF-κB in RAW 264.7 murine macrophage cells. Int. Immunopharmacol. 9 1323–1331.

    Not in our library10.1016/j.intimp.2009.08.001

  189. 189.

    Zhang B. Liu Z. Y. Li Y. Y. Luo Y. Liu M. L. Dong H. Y. (2011 ). Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur. J. Pharm. Sci. 44 573–579.

    Not in our library10.1016/j.ejps.2011.09.020

  190. 190.

    Zhang Q. Q. Ding Y. Lei Y. Qi C. L. He X. D. Lan T. (2014 ). Andrographolide suppress tumor growth by inhibiting TLR4/NF-κB signaling activation in insulinoma. Int. J. Biol. Sci. 10 404–414.

    Not in our library10.7150/ijbs.7723

  191. 191.

    Zhang Y. Wang S. Li Y. Xiao Z. Hu Z. Zhang J. (2008 ). Sophocarpine and matrine inhibit the production of TNF-α and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. Int. Immunopharmacol. 8 1767–1772.

    Not in our library10.1016/j.intimp.2008.08.008

  192. 192.

    Zhao F. Nozawa H. Daikonnya A. Kondo K. Kitanaka S. (2003 ). Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol. Pharm. Bull. 26 61–65.

    Not in our library10.1248/bpb.26.61

  193. 193.

    Ziyan L. Yongmei Z. Nan Z. Ning T. Baolin L. (2007 ). Evaluation of the anti-inflammatory activity of luteolin in experimental animal models. Planta Med. 73 221–226.

    Not in our library10.1055/s-2007-967122

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.